Sant Pau - Institut de Recerca

Principals línies de recerca

Projectes sanitaris.
Estudis de mecanismes patogènics que alteren la distribució de grassa corporal.
Estudi de trastorns metabòlics associats al tractament antiretroviral.
Canvis en la composició corporal.
Nous fàrmacs antiretrovirals.
Risc cardiovascular associat al tractament antiretroviral.
Condicions de comorbiditat associades a la infecció per VIH-1.
Farmacogenètica (toxicocinètica).
Meningitis bacteriana.

Reptes

Projectes sanitaris

Continuïtat, expansió i consolidació de l’equip d’atenció de pacients infectats amb VIH-1, que actualment consisteix en 3 metges, 4 investigadors associats subvencionats (incloent un investigador Rio Hortega) i 2 infermeres.
Continuïtat en la participació en projectes multicèntrics (especialment en la xarxa SIDA, Gesida, VACH, EuroSIDA i col·laboració ART).
Exploració de possibles participacions en assaigs clínics amb nous fàrmacs antiretrovirals.
Incrementar el número de pacients amb VIH-1 que fan seguiment al nostre Hospital (donada l’actual taxa de mortalitat, es requereix un increment anual de 50 pacients).
Continuïtat amb els assaigs clínics en desenvolupament actualment i amb les línies de recerca clínica bàsiques.

Mecanismes patogènics que alteren la distribució de grassa corporal

Estudi del metabolisme en pirimidines i derivats en la gènesi de lipodistròfia associada a VIH-1 i tractament antiretroviral.
Desenvolupament d’un model animal (ratolí) per lipodistròfia.
Desenvolupament de models in vitro (cultius d’adipòcits) per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.
Estudi de les noves manifestacions del síndrome de lipodistròfia.
Desenvolupament de mesures per la concentració de fàrmacs antiretrovirals en el teixit adipós.
Exploració del rol de la inflamació en la patogènesi de lipodistròfia associada a VIH-1 i tractament antiretroviral.
Metabolisme de l’uridina i el seu rol en la patogènesi de la lipodistròfia.

Trastorns metabòlics associats al tractament antiretroviral

Valoració in vivo de la toxicitat metabòlica associada al tractament antiretroviral.
Desenvolupament de models in vitro (cultius d’adipòcits) per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.
Estudi dels factors que contribueixen a l’esteatosis hepàtica en pacients amb tractament antiretroviral.
Estudi del rol patogènic de l’FGF21 en la resistència a la insulina en pacients amb VIH-1.
Estudi del rol de FABP4 en trastorns metabòlics associats al tractament antiretroviral.

Composició corporal

Definició de la distribució normal de greix en la població general.
Establir patrons de distribució anormal de greix.
Desenvolupament d’una definició de lipodistròfia associada a VIH-1 i tractament antiretroviral.

Nous fàrmacs antiretrovirals

Assaigs clínics de nous fàrmacs antiretrovirals (fase II i III).
Potenciació farmacocinètica de ritonavir i no ritonavir en fàrmacs antiretrovirals.

Risc cardiovascular associat al tractament antiretroviral

Establiment d’una cohort de risc cardiovascular multicentre.
Estudi de factors dependents de tractament antiretroviral i no dependents en cohorts multicentre.
Desenvolupament de models in vitro (cultius d’adipòcits per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.

Condicions de comorbiditat associades a la infecció per VIH-1

Estudi de l’envelliment en diferents teixits associats a la infecció per VIH-1 i tractaments antiretrovirals.
Estudi de la fragilitat en pacients amb infecció per VIH-1 i el rol de HAART.
Avaluació de la funció neurocognitiva en pacients amb infecció per VIH-1 amb i sense tractament antiretroviral.
Participació en estudis multicèntrics de cohort per determinar la incidència de comorbiditats específiques (càncer, hepatitis C, malaltia cardiovascular, osteogènesi/osteoporosi): EuroSIDA, Col·laboració ART, Gesida, VACH, etc.
Tractament de l’hepatitis C en pacients amb VIH-1 i el seu pronòstic.

Farmacogenètica (toxicocinètica)

Rol del polimorfisme enzimàtic de les rutes de la pirimidina en la patogènesi de lipodistròfia.
Rol del polimorfisme enzimàtic de les rutes de la pirimidina en la patogènesi de toxicitat clínica (neuropaties, pancreatitis).
Rol del polimorfisme d’IL28B en cura espontània d’hepatitis C com a resposta a tractaments antiretrovirals basats en interferó i ribavirin.

Meningitis bacteriana

Identificació de factors de pronòstic en meningitis bacteriana adulta.
Comunicació amb un estudi de cohort de meningitis bacteriana adulta.
Identificació de factors d’hoste intrínsec en la patogènesi i prognosi de meningitis bacteriana adulta i malaltia meningococal.

Coordinació del grup

DOMINGO PEDROL, PERE FGS
pdomingo@santpau.cat

Membres

Herrera Bachs, Silvia IR

Millan Revilla, Lucia IR

Muñoz Rodriguez, Jessica IR

Quesada Lopez, Tania Paloma IR

Publicacions 2023

(JIF 2023)

-Berenguer J, Jarrín I, Bellón JM, Díez C, Jiménez MA, Roca C, González J, Dalmau D, Olalla J, Herrero C, Villarroya F, Domingo P, Resino S. Obesity-Related Single-Nucleotide Polymorphisms and Weight Gain following First-Line Antiretroviral Therapy. CLINICAL INFECTIOUS DISEASES. 2023; 76(6). DOI:10.1093/cid/ciac880. PMID:36345912. IF:8,200 (Q1/1D). Document type: Article.

-Bruguera A, Nomah D, Moreno S, Diaz Y, Aceiton J, Reyes J, Ambrosioni J, Llibre JM, Falco V, Imaz A, Fanjul F, Navarro G, Pere D, Leon E, Mera A, Miro JM, Casabona J, PISCIS GRP. Cohort Profile: PISCIS, a population-based cohort of people living with HIV in Catalonia and Balearic Islands. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2023; 52(4):e241-e252. DOI:10.1093/ije/dyad083. PMID:37403345. IF:6,400 (Q1/1D). Document type: Article.

-Castella M, Blasco A, Peyrou M, Gavalda A, Villarroya J, Quesada T, Lorente L, Sancho J, Szymczak F, Piron A, Rodriguez S, Carobbio S, Goday A, Domingo P, Vidal A, Giralt M, Eizirik DL, Villarroya F, Cereijo R. Adipose tissue plasticity in pheochromocytoma patients suggests a role of the splicing machinery in human adipose browning. iScience. 2023; 26(6):106847. DOI:10.1016/j.isci.2023.106847. PMID:37250773. IF:4,600 (Q1/2D). Document type: Article.

-Díaz M, Casano P, Quesada T, López A, de Zegher F, Villarroya F, Ibáñez L. Circulating exosomes decrease in size and increase in number between birth and age 7: relations to fetal growth and liver fat. Frontiers in Endocrinology. 2023; 14:1257768. DOI:10.3389/fendo.2023.1257768. PMID:38027180. IF:3,900 (Q2/3D). Document type: Article.

-Diaz M, Mestres A, Lerin C, Cereijo R, Lopez A, de Zegher F, Villarroya F, Ibanez L. Circulating progranulin in human infants: relation to prenatal growth and early postnatal nutrition. PEDIATRIC RESEARCH. 2023; 94(3). DOI:10.1038/s41390-023-02595-1. PMID:37031297. IF:3,100 (Q1/2D). Document type: Article.

-Garcia C, Navarro A, Lopez A, Quesada T, de Zegher F, Ibanez L, Villarroya F. Meteorin-like levels are associated with active brown adipose tissue in early infancy. Frontiers in Endocrinology. 2023; 14:1136245. DOI:10.3389/fendo.2023.1136245. PMID:36936161. IF:3,900 (Q2/3D). Document type: Article.

-González A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E, NEAT Study Group 022. Long-term effects on subclinical cardiovascular disease of switching from boosted protease inhibitors to dolutegravir. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2023; 78(9). DOI:10.1093/jac/dkad247. PMID:37539492. IF:3,900 (Q1/3D). Document type: Article.

-Martín R, Pericas C, Bruguera A, Rosell G, Martínez E, Díaz Y, Alonso L, Nomah DK, Blanco JL, Domingo P, Alvarez P, Linares MS, Laborda CV, Mera A, Isbert SC, Johansen IS, Miró JM, Casabona J, Llibre JM, PISCIS GRP. Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study. Microorganisms. 2023; 11(11):2701. DOI:10.3390/microorganisms11112701. PMID:38004713. IF:4,100 (Q2/4D). Document type: Article.

-Martín R, Vazquez MC, Burgos J, Bruguera A, Reyes J, Moreno S, Aceitón J, Díaz Y, Domingo P, Saumoy M, Knobel H, Dalmau D, Borjabad B, Johansen IS, Miro JM, Casabona J, Llibre JM, PISCIS G. Cardiovascular events in delayed presentation of HIV: the prospective PISCIS cohort study. Frontiers in Medicine. 2023; 10:1182359. DOI:10.3389/fmed.2023.1182359. PMID:37415770. IF:3,100 (Q1/2D). Document type: Article.

-Palacio J, Moreno S, Díaz Y, Aceitón J, Bruguera A, Nomah DK, Llibre JM, Knobel H, Chivite I, Miro JM, Domingo P, Suanzes P, Fanjul F, Navarro G, Macorigh L, Mera A, Casabona J, Imaz A, Reyes J, ISCIS GRP. Who is lost to follow-up in HIV care? Assessment of care retention over time and the impact of COVID-19. Longitudinal analysis of the PISCIS cohort. HIV MEDICINE. 2023; 24(9). DOI:10.1111/hiv.13486. PMID:36990962. IF:2,800 (Q2/5D). Document type: Article.

-Pomar V, Benito N, Duch P, Colome M, Rivera A, Domingo P. Acute Bacterial Meningitis in Healthy Adult Patients: A Prospective Cohort Study. Journal of Clinical Medicine. 2023; 12(11):3624. DOI:10.3390/jcm12113624. PMID:37297818. IF:3,000 (Q1/2D). Document type: Article.

-Santos JR, Casadellà M, Noguera M, Micán R, Domingo P, Antela A, Portilla J, Sanz J, Montero M, Navarro J, Masiá M, Valcarce N, Ocampo A, Pérez L, García C, Vivancos MJ, Imaz A, Iribarren JA, Hernández J, Villar J, Barrufet P, Paredes R, INSTINCT GRP. Effectiveness and safety of integrase strand transfer inhibitors in Spain: a prospective real-world study. Frontiers in Cellular and Infection Microbiology. 2023; 13:1187999. DOI:10.3389/fcimb.2023.1187999. PMID:37434782. IF:4,600 (Q1/3D). Document type: Article.

-Santos JR, Domingo P, Portilla J, Gutiérrez F, Imaz A, Vilchez H, Curran A, Valcarce N, Payeras A, Bernal E, Montero M, Yzusqui M, Clotet B, Videla S, Moltó J, Paredes R, Study 2DGRP. A Randomized Trial of Dolutegravir Plus Darunavir/Cobicistat as a Switch Strategy in HIV-1-Infected Patients With Resistance to at Least 2 Antiretroviral Classes. Open Forum Infectious Diseases. 2023; 10(11):ofad542. DOI:10.1093/ofid/ofad542. PMID:38023553. IF:3,800 (Q2/3D). Document type: Article.

-Scévola S, Niubó J, Domingo P, Verdejo G, Curran A, Diaz V, Peñafiel J, Tiraboschi J, Morenilla S, Garcia B, Soriano I, Podzamczer D, Imaz A. Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide. JOURNAL OF INFECTIOUS DISEASES. 2023; 228(7). DOI:10.1093/infdis/jiad304. PMID:37526315. IF:5,000 (Q1/2D). Document type: Article.

-Sempere A, Assoumou L, Gonzalez A, Waters L, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masia M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell J, Pozniak A, Martinez E, NEAT 022GRP. Incidence of Hypertension and Blood Pressure Changes in Persons With Human Immunodeficiency Virus (HIV) at High Risk for Cardiovascular Disease Switching From Boosted Protease Inhibitors to Dolutegravir: A Post-hoc Analysis of the 96-week Randomised NEAT-022 Trial. CLINICAL INFECTIOUS DISEASES. 2023; 77(7). DOI:10.1093/cid/ciad297. PMID:37207617. IF:8,200 (Q1/1D). Document type: Article.

-Waters L, Assoumou L, Gonzalez A, Rusconi S, Domingo P, Gompels M, de Wit S, Raffi F, Stephan C, Masia M, Rockstroh J, Katlama C, Behrens GMN, Moyle G, Johnson M, Fox J, Stellbrink HJ, Guaraldi G, Florence E, Esser S, Gatell JM, Pozniak A, Martinez E, NEAT 022GRP. Limited Weight Impact After Switching From Boosted Protease Inhibitors to Dolutegravir in Persons With Human Immunodeficiency Virus With High Cardiovascular Risk: A Post Hoc Analysis of the 96-Week NEAT-022 Randomized Trial. CLINICAL INFECTIOUS DISEASES. 2023; 76(5). DOI:10.1093/cid/ciac827. PMID:36259527. IF:8,200 (Q1/1D). Document type: Article.

Publicacions 2022

(JIF 2022)

Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13212. PMID:34882940. IF:3 (Q3/7D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
Calvet J, Berenguer A, Gay M, Massanella M, Domingo P, Llop M, Sanchez E, Arevalo M, Carrillo J, Albinana N, Arauz G, Orellana C, Delgado JF, Serrano A, Llobell A, Graell E, Garcia M, Moreno M, Galisteo C, Casado E, Navarro N, Gomez A, Garcia S, Rusinol M, Costa E, Clotet B, Vilaseca M, Blanco J, Gratacos J. Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports. 2022; 12(1):640. DOI:10.1038/s41598-021-04683-w. PMID:35022497. IF:4,6 (Q2/3D). Document type: Article.
Castellvi I, Castillo D, Corominas H, Mariscal A, Orozco S, Benito N, Pomar V, Baucells A, Mur I, de la Rosa D, Lobo D, Millan AM, de Sosa NH, Filella D, Matas L, Martinez L, Juarez C, Casademont J, Domingo P. Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study. Frontiers in Medicine. 2022; 9:973918. DOI:10.3389/fmed.2022.973918. PMID:36004366. IF:3,9 (Q2/4D). Document type: Article.
Castro A, Diaz P, Domingo P, Garcia C, Losa JE, Castro A, Vidal N, Aceituno S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6). DOI:10.7399/fh.13038. PMID:36520571. Document type: Article.
Collazos J, Domingo P, Fernandez N, Asensi E, Vilchez H, Lalueza A, Roy E, Blanes R, Raya M, Sanz J, Artero A, Ramos JM, Duenas C, Lamas JL, Asensi V, Valproic Acid COVID GRP. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022; 17(1):e0262777. DOI:10.1371/journal.pone.0262777. PMID:35085321. IF:3,7 (Q2/4D). Document type: Article.
Cozzi A, Peters L, Pelchen A, Neesgaard B, Stephan C, Elbirt D, Brännström J, Paduta D, Trofimova T, Szlavik J, Van V, Pai H, Lundgren J, Harxhi A, Losso M, Kundro M, Schmied B, Karpov I, Vassilenko A, Paduto D, Mitsura VM, Clumeck N, De Wit S, Delforge M, Hadziosmanovic V, Begovac J, Machala L, Jilich D, Gerstoft J, Pedersen C, Sedlacek D, et al. [Domingo P], for the EuroSIDA Study Group. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy. 2022; 19(1):38. DOI:10.1186/s12981-022-00457-0. PMID:35933352. IF:2,2 (Q4/8D). Document type: Article.
De Dios A, Masip M, Pagès N, Riera P, Mateo MG, Del Mar M, Mangues MA, Gomis M. Desarrollo de una intervención mHealth para rediseñar la ruta asistencial de las personas que viven con VIH: Estudio cualitativo. Farmacia Hospitalaria. 2022; 46. DOI:10.7399/fh.13249. PMID:36520560. Document type: Article.
Domingo P, Giralt M, Gavalda A, Blasco A, Delgado A, Gallego JM, Gutierrez MD, Mateo MG, Cereijo R, Domingo JC, Villarroya F, Villarroya J. Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy. 2022; 11(1):2042962. DOI:10.1080/21623945.2022.2042962. PMID:35300561. IF:3,3 (Q3/6D). Document type: Article.
Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderros L, Gallego JM, Gutierrez MD, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine. 2022; 11(3):549. DOI:10.3390/jcm11030549. PMID:35160008. IF:3,9 (Q2/4D). Document type: Article.
Domingo P, Quesada T, Villarroya J, Cairo M, Gutierrez MD, Mateo MG, Mur I, Corbacho N, Domingo JC, Villarroya F, Giralt M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308:120948. DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6,1 (Q1/2D). Document type: Article.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Tellez MJ, Dominguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero A, Santos I, Giner L, Arminanzas C, Montero M, Manzardo C, Cifuentes C, Garcia C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodriguez C, Gaspar G, Perez L, Losa JE, Force L, Veloso S, Martinez E, Jarrin I, De Miguel M, Garcia JG. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV MEDICINE. 2022; 23(7). DOI:10.1111/hiv.13229. PMID:35037379. IF:3 (Q3/7D). Document type: Article.
Franquet T, Domingo P. Pulmonary Infections in People Living with HIV. RADIOLOGIC CLINICS OF NORTH AMERICA. 2022; 60(3). DOI:10.1016/j.rcl.2022.01.008. PMID:35534134. IF:1,9 (Q3/8D). Document type: Review.
Franquet T, Gimenez A, Ketai L, Mazzini S, Rial A, Pomar V, Domingo P. Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. EUROPEAN RADIOLOGY. 2022; 32(7). DOI:10.1007/s00330-022-08580-2. PMID:35226158. IF:5,9 (Q1/2D). Document type: Article.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:2,5 (Q3/6D). Document type: Article.
Garcia C, Cereijo R, Plou C, Gavalda A, Malpique R, Villarroya J, Lopez A, de Zegher F, Ibanez L, Villarroya F. Posterior Cervical Brown Fat and CXCL14 Levels in the First Year of Life: Sex Differences and Association With Adiposity. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022; 107(3). DOI:10.1210/clinem/dgab761. PMID:34677618. IF:5,8 (Q1/3D). Document type: Article.
Garreta E, Prado P, Stanifer ML, Monteil V, Marco A, Ullate A, Moya D, Vilas A, Tarantino C, Romero JP, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo M, González F, Domingo P, Gavaldà A, del Pozo CH, Hasan O, Ventura P, Campistol JM, Prosper F, Mirazimi A, Boulant S, Penninger JM, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabolism. 2022; 34(6). DOI:10.1016/j.cmet.2022.04.009. PMID:35561674. IF:29 (Q1/1D). Document type: Article.
Gavalda A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: An update on actors and actions. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2022; 23(1). DOI:10.1007/s11154-021-09640-6. PMID:33712997. IF:8,2 (Q1/1D). Document type: Review.
Llaurado G, Vlacho B, Wargny M, Ruan Y, Franch J, Domingo P, Gourdy P, Saulnier PJ, Hadjadj S, Wild SH, Rea R, Cariou B, Khunti K, Mauricio D. The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19). Cardiovascular Diabetology. 2022; 21(1):216. DOI:10.1186/s12933-022-01657-8. PMID:36261811. IF:9,3 (Q1/1D). Document type: Article.
Martin R, Reyes J, Bruguera A, Aceitón J, Díaz Y, Moreno S, Domingo P, Burgos J, Tiraboschi JM, Johansen IS, Álvarez H, Miró JM, Casabona J, Llibre JM, PISCIS G. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. Eclinicalmedicine. 2022; 52:101600. DOI:10.1016/j.eclinm.2022.101600. PMID:35958520. IF:15,1 (Q1/1D). Document type: Article.
Masip J, Jorba R, Lopez M, Domingo P, Pacheco YM, Garcia G, Martinez E, Vilades C, Veloso S, Alba V, Olona M, Vidal F, Gomez F, Peraire J, Rull A. Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(15):8071. DOI:10.3390/ijms23158071. PMID:35897644. IF:5,6 (Q1/3D). Document type: Article.
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Foppa CU, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13210. PMID:34889022. IF:3 (Q3/7D). Document type: Article.
Moga E, Lynton E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology. 2022; 13:904686. DOI:10.3389/fimmu.2022.904686. PMID:35833134. IF:7,3 (Q1/3D). Document type: Review.
Munoz J, Millan L. The role of nurses in the prevention of anal cancer in HIV- infected men having sex with men – a focus on papillomavirus vaccination and anal cytology screening. AIDS REVIEWS. 2022; 24(4). DOI:10.24875/AIDSRev.M22000053. PMID:36580603. IF:2,2 (Q4/8D). Document type: Review.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM, PISCIS GRP. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(8). DOI:10.1093/jac/dkac177. PMID:35678461. IF:5,2 (Q1/2D). Document type: Article.
Podzamczer D, Mican R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masia M, Gomez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro A, Bernal E, Vinuesa D, Knobel H, Troya J, Macias J, Montero M, Sanz J, Navarro A, Caicedo A, Fernandez G, Martinez E, Moreno S, SYMTRI I. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3):ofab595. DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4,2 (Q2/4D). Document type: Article.
Reyes D, Lopez J, Moga E, Pla F, Lynton E, Rojas R, Turon J, Querol L, Olive M, Alvarez R, Caballero M, Carbayo A, Vesperinas A, Domingo P, Illa I, Gallardo E, Cortes E. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(4):e200002. DOI:10.1212/NXI.0000000000200002. PMID:35728947. IF:8,8 (Q1/1D). Document type: Article.
Riancho JA, Peris P, González J, Pérez JL, Cannata J, Cano A, Carbonell C, Casado E, Ciria M, Corral L, del Pino J, Del Río LM, Díaz M, Díez A, García A, Gómez C, Gómez de Tejada Romero MJ, Guañabens N, Hawkins F, Jódar E, Malouf J, Martínez Díaz G, Monegal A, Muñoz M, Naves M, Nogues X, Nolla JM, Olmos JM, Peris P, Quesada JM, Rodríguez M, Sosa M, Torrijos A, Valero Díaz de Lamadrid C, SEIOMM Osteoporosis Guidelines Writing G. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1). DOI:10.4321/S1889-836X2022000100002. Document type: Article.
Saumoy M, Sanchez JL, Assoumou L, Gatell JM, Gonzalez A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masia M, Ordonez J, Pozniak A, Martinez E, Podzamczer D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(7). DOI:10.1093/jac/dkac117. PMID:35411401. IF:5,2 (Q1/2D). Document type: Article/Practice guideline.
Spinner CD, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, Stephan CJ, DeGrosky M, Bainbridge V, Zhan J, Dumitrescu TP, Jeffrey JL, Xu JF, Halliday F, Gan JJ, Johnson M, Gartland M, Joshi SR, Lataillade M, Study 208132. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. CLINICAL INFECTIOUS DISEASES. 2022; 75(5). DOI:10.1093/cid/ciab1065. PMID:34996113. IF:11,8 (Q1/1D). Document type: Article.
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6). DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:16,1 (Q1/1D). Document type: Article.
Yeregui E, Masip J, Vilades C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, Garcia G, Negredo E, Olona M, Vidal J, Peraire M, Marti A, Reverte L, Gomez F, Leal M, Vidal F, Peraire J, Rull A. Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4):2202. DOI:10.3390/ijms23042202. PMID:35216318. IF:5,6 (Q1/3D). Document type: Article.

Publicacions 2021

Alserawan L, Penacoba P, Echevarria S, Castillo D, Ortiz E, Martinez L, Naranjo EM, Domingo P, Castellvi I, Juarez C, Mariscal A. Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics. 2021; 11(11):1998. DOI:10.3390/diagnostics11111998. PMID:34829345. IF:3,992.
Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jablonowska E, Ostergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A, Group ES. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2021; 86(2). DOI:10.1097/QAI.0000000000002541. PMID:33079903. IF:3,771.
Arroyo JA, Julve J, Vlacho B, Corcoy R, Ponte P, Roman E, Navas E, Llaurado G, Franch J, Domingo P, Mauricio D. Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health. 2021; 9:758347. DOI:10.3389/fpubh.2021.758347. PMID:34631653. IF:6,461.
Berenguer J, Borobia AM, Ryan P, Rodriguez J, Bellon JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Mancebo J, MARTIN A. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. THORAX. 2021; 76(9). DOI:10.1136/thoraxjnl-2020-216001. PMID:33632764. IF:9,102.
Brochado O, Martinez I, Berenguer J, Medrano L, Gonzalez J, Jimenez MA, Carrero A, Hontanon V, Navarro J, Guardiola JM, Fernandez A, Resino S, Domingo P, Esteban H. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. JOURNAL OF BIOMEDICAL SCIENCE. 2021; 28(1):23. DOI:10.1186/s12929-021-00718-6. PMID:33785040. IF:12,771.
Camps A, Perez S, Subirana I, Teira R, Estrada V, Domingo P, Degano IR, Marrugat J. Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population. Journal of Personalized Medicine. 2021; 11(11):1085. DOI:10.3390/jpm11111085. PMID:34834438. IF:3,508.
Cereijo R, Quesada T, Gavalda A, Tarasco J, Pellitero S, Reyes M, Puig M, Giralt M, Sanchez D, Villarroya F. The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans. INTERNATIONAL JOURNAL OF OBESITY. 2021; 45(3). DOI:10.1038/s41366-020-00732-y. PMID:33414488. IF:5,551.
Corbacho N, Mur I, Molas ME, Vidal F, Domingo P. The pharmacological management of cardiovascular disease in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(6). DOI:10.1080/14656566.2020.1856075. PMID:33283570. IF:4,103.
Corominas H, Castellvi I, Diaz C, Matas L, de la Rosa D, Mangues MA, Moya P, Pomar V, Benito N, Moga E, Hernandez N, Casademont J, Domingo P. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. MEDICINE. 2021; 100(19):e25923. DOI:10.1097/MD.0000000000025923. PMID:34106658. IF:1,817.
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF:10,190.
Domingo P, Pomar V, Mur I, Castellvi I, Corominas H, de Benito N. Not all COVID-19 pandemic waves are alike. CLINICAL MICROBIOLOGY AND INFECTION. 2021; 27(7). DOI:10.1016/j.cmi.2021.04.005. PMID:33887469. IF:13,310.
Elias MJP, Alejos B, Gutierrez MM, Crespo M, Gil ID, Ribera E, Galindo MJ, Lozano F, Cifre AP, Boix V, Montero M, Sanz J, Lima JD, Palacios R, Moral SDF, Martinez E. Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(4). DOI:10.1093/jac/dkaa547. PMID:33501995. IF:5,758.
Fernández I, de Lazzari E, Inciarte A, Diaz-Brito V, Milinkovic A, Arenas-Pinto A, Etcheverrry F, García F, Leal L; HIV-PEP Group [Domingo P]. Network meta-analysis of post-exposure prophylaxis randomized clinical trials. HIV Medicine. 2021;22(3):218-224. DOI:10.1111/hiv.12964. PMID: 33108035. IF:3,094.
Gonzalez A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martinez E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9). DOI:10.1093/jac/dkab158. PMID:34120186. IF:5,758.
Grau B, Camprubi D, Marti H, Fernandez M, Carreras C, Velasco M, Ferrer E, Muelas M, Jullien S, Barilaro G, Ajanovic S, Vera I, Moreno L, Gonzalez E, Cortes N, Roldan M, Artes A, Mur I, Domingo P, Garcia F, Guinovart C, Munoz J. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021; 22(1):808. DOI:10.1186/s13063-021-05758-9. PMID:34781981. IF:2,728.
Gutierrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachon J, Carratala J, Berenguer J, Arribas JR, Rodriguez J, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Puig M, Mancebo J, Martinez G. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. LANCET INFECTIOUS DISEASES. 2021; 21(6). DOI:10.1016/S1473-3099(21)00019-0. PMID:33636145. IF:71,421.
Gutierrez MD, Mur I, Mateo MG, Vidal F, Domingo P. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(9). DOI:10.1080/14656566.2021.1887140. PMID:33634724. IF:4,103.
Kowalska JD, Pelchen A, Ryom L, Losso MH, Trofimova T, Mitsura VM, Khromova I, Paduta D, Stephan C, Domingo P, Bakowska E, Monforte AD, Oestergaard L, Jablonowska E, Kuznetsova A, Moreno S, Vasylyev M, Pradier C, Battegay M, Vandekerckhove L, Castagna A, Raben D, Mocroft A, EuroSIDA GRP. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. AIDS. 2021; 35(12). DOI:10.1097/QAD.0000000000002954. PMID:34033590. IF:4,632.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Llibre JM, Domingo P, Falco V, Imaz A, Cortes C, Force L, Letang E, Vilaro I, Casabona J, Miro JM, Mur I, Macorigh L. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11). DOI:10.1016/S2352-3018(21)00240-X. PMID:34655549. IF:16,070.
Ortega E, Corcoy R, Gratacos M, Claramunt FXC, Mata M, Puig R, Real J, Vlacho B, Castelblanco E, Domingo P, Khunti K, Franch J, Mauricio D. Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open. 2021; 11(7):e051237. DOI:10.1136/bmjopen-2021-051237. PMID:34301668. IF:3,006.
Palacio J, Reyes JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaro I, Borras FH, Falco V, Riera M, Domingo P, de Lazzari E, Miro JM, Casabona J, Gurgui M, Hernandez J. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC PUBLIC HEALTH. 2021; 21(1):1596. DOI:10.1186/s12889-021-11613-y. PMID:34454444. IF:4,135.
Reyes M, Gonzalez L, Ibeas K, Cereijo R, Taxeras SD, Pellitero S, Martinez E, Tarasco J, Moreno P, Malagon P, Higueras C, Soria A, Puig M, Villarroya F, Serra D, Herrero L, Sanchez D. White adipose tissue-infiltrated CD11b+myeloid cells are a source of S100A4, a new potential marker of hepatic damage. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2021; 184(4). DOI:10.1530/EJE-20-1130. PMID:33524007. IF:6,558.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martinez E, DOLAM GRP. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8). PMID:34358497. IF:16,070.
Shankar M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez A, Feuth T, Garcia F, Garcia R, Gonzalez I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, et al. [Pomar V, Benito N]. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2021; 326(6). DOI:10.1001/jama.2021.11330. PMID:34228774. IF:157,335.
Teira R, Diaz H, Aragao F, Marguet S, de la Fuente B, Munoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martinez E, Geijo P, Estrada V, Garcia J, Sepulveda MA, Berenguer J. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS One. 2021; 16(4):e0249515. DOI:10.1371/journal.pone.0249515. PMID:33831047. IF:3,752.
Teira R, Diaz H, Aragao F, Munoz J, Galindo P, Merino M, de la Fuente B, Sepulveda MA, Domingo P, Garcia J, Castano M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martinez E, Estrada V, Montero M, Berenguer J, Espinosa N. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research & Clinical Practice. 2021; 22(3). DOI:10.1080/25787489.2021.1955197. PMID:34410219. IF:1,676.
Urraza AI, Giralt M, Gonzalez FF, Villarroya F, Perez A, Flores PR, Perez M, Domingo P, Lopez FC. FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). PLoS One. 2021; 16(5):e0252144. DOI:10.1371/journal.pone.0252144. PMID:34019585. IF:3,752.
Vilchez HH, Escudero R, Fernandez M, Murillo O, Aunon A, Rodriguez D, Jover A, del Toro MD, Rico A, Falgueras L, Praena J, Guio L, Iribarren JA, Lora J, Benito N, Morata L, Ramirez A, Riera M, Mur I, Coll P, Crusi X, Soriano A. Prosthetic Shoulder Joint Infection by Cutibacterium acnes: Does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study. Antibiotics-Basel. 2021; 10(5):475. DOI:10.3390/antibiotics10050475. PMID:33919103. IF:5,222.

2017 Scientific Report – Research Group in HIV

presentació

Principals línies de recerca

Projectes sanitaris.
Estudis de mecanismes patogènics que alteren la distribució de grassa corporal.
Estudi de trastorns metabòlics associats al tractament antiretroviral.
Canvis en la composició corporal.
Nous fàrmacs antiretrovirals.
Risc cardiovascular associat al tractament antiretroviral.
Condicions de comorbiditat associades a la infecció per VIH-1.
Farmacogenètica (toxicocinètica).
Meningitis bacteriana.

Reptes

Projectes sanitaris

Continuïtat, expansió i consolidació de l’equip d’atenció de pacients infectats amb VIH-1, que actualment consisteix en 3 metges, 4 investigadors associats subvencionats (incloent un investigador Rio Hortega) i 2 infermeres.
Continuïtat en la participació en projectes multicèntrics (especialment en la xarxa SIDA, Gesida, VACH, EuroSIDA i col·laboració ART).
Exploració de possibles participacions en assaigs clínics amb nous fàrmacs antiretrovirals.
Incrementar el número de pacients amb VIH-1 que fan seguiment al nostre Hospital (donada l’actual taxa de mortalitat, es requereix un increment anual de 50 pacients).
Continuïtat amb els assaigs clínics en desenvolupament actualment i amb les línies de recerca clínica bàsiques.

Mecanismes patogènics que alteren la distribució de grassa corporal

Estudi del metabolisme en pirimidines i derivats en la gènesi de lipodistròfia associada a VIH-1 i tractament antiretroviral.
Desenvolupament d’un model animal (ratolí) per lipodistròfia.
Desenvolupament de models in vitro (cultius d’adipòcits) per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.
Estudi de les noves manifestacions del síndrome de lipodistròfia.
Desenvolupament de mesures per la concentració de fàrmacs antiretrovirals en el teixit adipós.
Exploració del rol de la inflamació en la patogènesi de lipodistròfia associada a VIH-1 i tractament antiretroviral.
Metabolisme de l’uridina i el seu rol en la patogènesi de la lipodistròfia.

Trastorns metabòlics associats al tractament antiretroviral

Valoració in vivo de la toxicitat metabòlica associada al tractament antiretroviral.
Desenvolupament de models in vitro (cultius d’adipòcits) per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.
Estudi dels factors que contribueixen a l’esteatosis hepàtica en pacients amb tractament antiretroviral.
Estudi del rol patogènic de l’FGF21 en la resistència a la insulina en pacients amb VIH-1.
Estudi del rol de FABP4 en trastorns metabòlics associats al tractament antiretroviral.

Composició corporal

Definició de la distribució normal de greix en la població general.
Establir patrons de distribució anormal de greix.
Desenvolupament d’una definició de lipodistròfia associada a VIH-1 i tractament antiretroviral.

Nous fàrmacs antiretrovirals

Assaigs clínics de nous fàrmacs antiretrovirals (fase II i III).
Potenciació farmacocinètica de ritonavir i no ritonavir en fàrmacs antiretrovirals.

Risc cardiovascular associat al tractament antiretroviral

Establiment d’una cohort de risc cardiovascular multicentre.
Estudi de factors dependents de tractament antiretroviral i no dependents en cohorts multicentre.
Desenvolupament de models in vitro (cultius d’adipòcits per estudiar la toxicitat adiposa dels fàrmacs antiretrovirals.

Condicions de comorbiditat associades a la infecció per VIH-1

Estudi de l’envelliment en diferents teixits associats a la infecció per VIH-1 i tractaments antiretrovirals.
Estudi de la fragilitat en pacients amb infecció per VIH-1 i el rol de HAART.
Avaluació de la funció neurocognitiva en pacients amb infecció per VIH-1 amb i sense tractament antiretroviral.
Participació en estudis multicèntrics de cohort per determinar la incidència de comorbiditats específiques (càncer, hepatitis C, malaltia cardiovascular, osteogènesi/osteoporosi): EuroSIDA, Col·laboració ART, Gesida, VACH, etc.
Tractament de l’hepatitis C en pacients amb VIH-1 i el seu pronòstic.

Farmacogenètica (toxicocinètica)

Rol del polimorfisme enzimàtic de les rutes de la pirimidina en la patogènesi de lipodistròfia.
Rol del polimorfisme enzimàtic de les rutes de la pirimidina en la patogènesi de toxicitat clínica (neuropaties, pancreatitis).
Rol del polimorfisme d’IL28B en cura espontània d’hepatitis C com a resposta a tractaments antiretrovirals basats en interferó i ribavirin.

Meningitis bacteriana

Identificació de factors de pronòstic en meningitis bacteriana adulta.
Comunicació amb un estudi de cohort de meningitis bacteriana adulta.
Identificació de factors d’hoste intrínsec en la patogènesi i prognosi de meningitis bacteriana adulta i malaltia meningococal.

equip

Coordinació del grup

DOMINGO PEDROL, PERE FGS
pdomingo@santpau.cat

Membres

Herrera Bachs, Silvia IR

Millan Revilla, Lucia IR

Muñoz Rodriguez, Jessica IR

Quesada Lopez, Tania Paloma IR

producció científica

Publicacions 2023

(JIF 2023)

Publicacions 2022

(JIF 2022)

Amele S, Sandri AK, Rodger A, Vandekerckhove L, Benfield T, Milinkovic A, Duvivier C, Stellbrink HJ, Sambatakou H, Chkhartishvili N, Caldeira L, Laguno M, Domingo P, Wandeler G, Gisinger M, Kuzovatova E, Dragovic G, Knysz B, Matulionyte R, Rockstroh JK, Lundgren JD, Mocroft A, Peters L. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13212. PMID:34882940. IF:3 (Q3/7D). Document type: Article.
Calabria M, Garcia C, Grunden N, Pons C, Arroyo JA, Gomez B, Garcia M, Belvis R, Morollon N, Igual JV, Mur I, Pomar V, Domingo P. Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. JOURNAL OF NEUROLOGY. 2022; 269(8). DOI:10.1007/s00415-022-11141-8. PMID:35488918. IF:6 (Q1/2D). Document type: Article.
Calvet J, Berenguer A, Gay M, Massanella M, Domingo P, Llop M, Sanchez E, Arevalo M, Carrillo J, Albinana N, Arauz G, Orellana C, Delgado JF, Serrano A, Llobell A, Graell E, Garcia M, Moreno M, Galisteo C, Casado E, Navarro N, Gomez A, Garcia S, Rusinol M, Costa E, Clotet B, Vilaseca M, Blanco J, Gratacos J. Biomarker candidates for progression and clinical management of COVID-19 associated pneumonia at time of admission. Scientific Reports. 2022; 12(1):640. DOI:10.1038/s41598-021-04683-w. PMID:35022497. IF:4,6 (Q2/3D). Document type: Article.
Castellvi I, Castillo D, Corominas H, Mariscal A, Orozco S, Benito N, Pomar V, Baucells A, Mur I, de la Rosa D, Lobo D, Millan AM, de Sosa NH, Filella D, Matas L, Martinez L, Juarez C, Casademont J, Domingo P. Krebs von den Lungen-6 glycoprotein circulating levels are not useful as prognostic marker in COVID-19 pneumonia: A large prospective cohort study. Frontiers in Medicine. 2022; 9:973918. DOI:10.3389/fmed.2022.973918. PMID:36004366. IF:3,9 (Q2/4D). Document type: Article.
Castro A, Diaz P, Domingo P, Garcia C, Losa JE, Castro A, Vidal N, Aceituno S. Analysis of the costs associated with the follow-up of HIV patients discontinuing antiretroviral treatment due to lack of effectiveness or unacceptable toxicity in Spain. Farmacia Hospitalaria. 2022; 46(6). DOI:10.7399/fh.13038. PMID:36520571. Document type: Article.
Collazos J, Domingo P, Fernandez N, Asensi E, Vilchez H, Lalueza A, Roy E, Blanes R, Raya M, Sanz J, Artero A, Ramos JM, Duenas C, Lamas JL, Asensi V, Valproic Acid COVID GRP. Exposure to valproic acid is associated with less pulmonary infiltrates and improvements in diverse clinical outcomes and laboratory parameters in patients hospitalized with COVID-19. PLoS One. 2022; 17(1):e0262777. DOI:10.1371/journal.pone.0262777. PMID:35085321. IF:3,7 (Q2/4D). Document type: Article.
Cozzi A, Peters L, Pelchen A, Neesgaard B, Stephan C, Elbirt D, Brännström J, Paduta D, Trofimova T, Szlavik J, Van V, Pai H, Lundgren J, Harxhi A, Losso M, Kundro M, Schmied B, Karpov I, Vassilenko A, Paduto D, Mitsura VM, Clumeck N, De Wit S, Delforge M, Hadziosmanovic V, Begovac J, Machala L, Jilich D, Gerstoft J, Pedersen C, Sedlacek D, et al. [Domingo P], for the EuroSIDA Study Group. Observational cohort study of rilpivirine (RPV) utilization in Europe. AIDS Research and Therapy. 2022; 19(1):38. DOI:10.1186/s12981-022-00457-0. PMID:35933352. IF:2,2 (Q4/8D). Document type: Article.
De Dios A, Masip M, Pagès N, Riera P, Mateo MG, Del Mar M, Mangues MA, Gomis M. Desarrollo de una intervención mHealth para rediseñar la ruta asistencial de las personas que viven con VIH: Estudio cualitativo. Farmacia Hospitalaria. 2022; 46. DOI:10.7399/fh.13249. PMID:36520560. Document type: Article.
Domingo P, Giralt M, Gavalda A, Blasco A, Delgado A, Gallego JM, Gutierrez MD, Mateo MG, Cereijo R, Domingo JC, Villarroya F, Villarroya J. Adipose tissue aging partially accounts for fat alterations in HIV lipodystrophy. 2022; 11(1):2042962. DOI:10.1080/21623945.2022.2042962. PMID:35300561. IF:3,3 (Q3/6D). Document type: Article.
Domingo P, Mateo MG, Villarroya J, Cereijo R, Torres F, Domingo JC, Campderros L, Gallego JM, Gutierrez MD, Mur I, Corbacho N, Vidal F, Villarroya F, Giralt M. Increased Circulating Levels of Growth Differentiation Factor 15 in Association with Metabolic Disorders in People Living with HIV Receiving Combined Antiretroviral Therapy. Journal of Clinical Medicine. 2022; 11(3):549. DOI:10.3390/jcm11030549. PMID:35160008. IF:3,9 (Q2/4D). Document type: Article.
Domingo P, Quesada T, Villarroya J, Cairo M, Gutierrez MD, Mateo MG, Mur I, Corbacho N, Domingo JC, Villarroya F, Giralt M. Differential effects of dolutegravir, bictegravir and raltegravir in adipokines and inflammation markers on human adipocytes. LIFE SCIENCES. 2022; 308:120948. DOI:10.1016/j.lfs.2022.120948. PMID:36096241. IF:6,1 (Q1/2D). Document type: Article.
Fanciulli C, Berenguer J, Busca C, Vivancos MJ, Tellez MJ, Dominguez L, Domingo P, Navarro J, Santos J, Iribarren JA, Morano L, Artero A, Moreno J, Rivero A, Santos I, Giner L, Arminanzas C, Montero M, Manzardo C, Cifuentes C, Garcia C, Galindo MJ, Ferrero OL, Sanz J, de la Fuente B, Rodriguez C, Gaspar G, Perez L, Losa JE, Force L, Veloso S, Martinez E, Jarrin I, De Miguel M, Garcia JG. Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019. HIV MEDICINE. 2022; 23(7). DOI:10.1111/hiv.13229. PMID:35037379. IF:3 (Q3/7D). Document type: Article.
Franquet T, Domingo P. Pulmonary Infections in People Living with HIV. RADIOLOGIC CLINICS OF NORTH AMERICA. 2022; 60(3). DOI:10.1016/j.rcl.2022.01.008. PMID:35534134. IF:1,9 (Q3/8D). Document type: Review.
Franquet T, Gimenez A, Ketai L, Mazzini S, Rial A, Pomar V, Domingo P. Air trapping in COVID-19 patients following hospital discharge: retrospective evaluation with paired inspiratory/expiratory thin-section CT. EUROPEAN RADIOLOGY. 2022; 32(7). DOI:10.1007/s00330-022-08580-2. PMID:35226158. IF:5,9 (Q1/2D). Document type: Article.
Garcia C, Calabria M, Grunden N, Pons C, Arroyo JA, Gomez B, Lleo A, Alcolea D, Belvis R, Morollon N, Mur I, Pomar V, Domingo P. Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain and Behavior. 2022; 12(3):e2508. DOI:10.1002/brb3.2508. PMID:35137561. IF:2,5 (Q3/6D). Document type: Article.
Garcia C, Cereijo R, Plou C, Gavalda A, Malpique R, Villarroya J, Lopez A, de Zegher F, Ibanez L, Villarroya F. Posterior Cervical Brown Fat and CXCL14 Levels in the First Year of Life: Sex Differences and Association With Adiposity. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM. 2022; 107(3). DOI:10.1210/clinem/dgab761. PMID:34677618. IF:5,8 (Q1/3D). Document type: Article.
Garreta E, Prado P, Stanifer ML, Monteil V, Marco A, Ullate A, Moya D, Vilas A, Tarantino C, Romero JP, Jonsson G, Oria R, Leopoldi A, Hagelkruys A, Gallo M, González F, Domingo P, Gavaldà A, del Pozo CH, Hasan O, Ventura P, Campistol JM, Prosper F, Mirazimi A, Boulant S, Penninger JM, Montserrat N. A diabetic milieu increases ACE2 expression and cellular susceptibility to SARS-CoV-2 infections in human kidney organoids and patient cells. Cell Metabolism. 2022; 34(6). DOI:10.1016/j.cmet.2022.04.009. PMID:35561674. IF:29 (Q1/1D). Document type: Article.
Gavalda A, Villarroya J, Cereijo R, Giralt M, Villarroya F. The endocrine role of brown adipose tissue: An update on actors and actions. REVIEWS IN ENDOCRINE & METABOLIC DISORDERS. 2022; 23(1). DOI:10.1007/s11154-021-09640-6. PMID:33712997. IF:8,2 (Q1/1D). Document type: Review.
Llaurado G, Vlacho B, Wargny M, Ruan Y, Franch J, Domingo P, Gourdy P, Saulnier PJ, Hadjadj S, Wild SH, Rea R, Cariou B, Khunti K, Mauricio D. The association between macrovascular complications and intensive care admission, invasive mechanical ventilation, and mortality in people with diabetes hospitalized for coronavirus disease-2019 (COVID-19). Cardiovascular Diabetology. 2022; 21(1):216. DOI:10.1186/s12933-022-01657-8. PMID:36261811. IF:9,3 (Q1/1D). Document type: Article.
Martin R, Reyes J, Bruguera A, Aceitón J, Díaz Y, Moreno S, Domingo P, Burgos J, Tiraboschi JM, Johansen IS, Álvarez H, Miró JM, Casabona J, Llibre JM, PISCIS G. Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. Eclinicalmedicine. 2022; 52:101600. DOI:10.1016/j.eclinm.2022.101600. PMID:35958520. IF:15,1 (Q1/1D). Document type: Article.
Masip J, Jorba R, Lopez M, Domingo P, Pacheco YM, Garcia G, Martinez E, Vilades C, Veloso S, Alba V, Olona M, Vidal F, Gomez F, Peraire J, Rull A. Lipoprotein Profile in Immunological Non-Responders PLHIV after Antiretroviral Therapy Initiation. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(15):8071. DOI:10.3390/ijms23158071. PMID:35897644. IF:5,6 (Q1/3D). Document type: Article.
Mocroft A, Miro JM, Wandeler G, Llibre JM, Boyd A, van K, Beniowski M, Mikhalik J, Cavassini M, Maltez F, Duvivier C, Foppa CU, Knysz B, Bakowska E, Kuzovatova E, Domingo P, Zagalo A, Viard JP, Degen O, Milinkovic A, Benfield T, Peters L. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. HIV MEDICINE. 2022; 23(6). DOI:10.1111/hiv.13210. PMID:34889022. IF:3 (Q3/7D). Document type: Article.
Moga E, Lynton E, Domingo P. The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology. 2022; 13:904686. DOI:10.3389/fimmu.2022.904686. PMID:35833134. IF:7,3 (Q1/3D). Document type: Review.
Munoz J, Millan L. The role of nurses in the prevention of anal cancer in HIV- infected men having sex with men – a focus on papillomavirus vaccination and anal cytology screening. AIDS REVIEWS. 2022; 24(4). DOI:10.24875/AIDSRev.M22000053. PMID:36580603. IF:2,2 (Q4/8D). Document type: Review.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Casabona J, Domingo P, Navarro J, Imaz A, Deig E, Navarro G, Llibre JM, Miro JM, PISCIS GRP. Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(8). DOI:10.1093/jac/dkac177. PMID:35678461. IF:5,2 (Q1/2D). Document type: Article.
Podzamczer D, Mican R, Tiraboschi J, Portilla J, Domingo P, Llibre JM, Ribera E, Vivancos MJ, Morano L, Masia M, Gomez C, Fanjul F, Payeras A, Inciarte A, Estrada V, Rivero A, Castro A, Bernal E, Vinuesa D, Knobel H, Troya J, Macias J, Montero M, Sanz J, Navarro A, Caicedo A, Fernandez G, Martinez E, Moreno S, SYMTRI I. Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57). Open Forum Infectious Diseases. 2022; 9(3):ofab595. DOI:10.1093/ofid/ofab595. PMID:35237700. IF:4,2 (Q2/4D). Document type: Article.
Reyes D, Lopez J, Moga E, Pla F, Lynton E, Rojas R, Turon J, Querol L, Olive M, Alvarez R, Caballero M, Carbayo A, Vesperinas A, Domingo P, Illa I, Gallardo E, Cortes E. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis. Neurology-Neuroimmunology & Neuroinflammation. 2022; 9(4):e200002. DOI:10.1212/NXI.0000000000200002. PMID:35728947. IF:8,8 (Q1/1D). Document type: Article.
Riancho JA, Peris P, González J, Pérez JL, Cannata J, Cano A, Carbonell C, Casado E, Ciria M, Corral L, del Pino J, Del Río LM, Díaz M, Díez A, García A, Gómez C, Gómez de Tejada Romero MJ, Guañabens N, Hawkins F, Jódar E, Malouf J, Martínez Díaz G, Monegal A, Muñoz M, Naves M, Nogues X, Nolla JM, Olmos JM, Peris P, Quesada JM, Rodríguez M, Sosa M, Torrijos A, Valero Díaz de Lamadrid C, SEIOMM Osteoporosis Guidelines Writing G. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update). Revista De Osteoporosis Y Metabolismo Mineral. 2022; 14(1). DOI:10.4321/S1889-836X2022000100002. Document type: Article.
Saumoy M, Sanchez JL, Assoumou L, Gatell JM, Gonzalez A, Guaraldi G, Domingo P, Giacomelli A, Connault J, Katlama C, Masia M, Ordonez J, Pozniak A, Martinez E, Podzamczer D. Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2022; 77(7). DOI:10.1093/jac/dkac117. PMID:35411401. IF:5,2 (Q1/2D). Document type: Article/Practice guideline.
Spinner CD, Felizarta F, Rizzardini G, Philibert P, Mitha E, Domingo P, Stephan CJ, DeGrosky M, Bainbridge V, Zhan J, Dumitrescu TP, Jeffrey JL, Xu JF, Halliday F, Gan JJ, Johnson M, Gartland M, Joshi SR, Lataillade M, Study 208132. Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254. CLINICAL INFECTIOUS DISEASES. 2022; 75(5). DOI:10.1093/cid/ciab1065. PMID:34996113. IF:11,8 (Q1/1D). Document type: Article.
Trickey A, Zhang L, Gill MJ, Bonnet F, Burkholder G, Castagna A, Cavassini M, Cichon P, Crane H, Domingo P, Grabar S, Guest J, Obel N, Psichogiou M, Rava M, Reiss P, Rentsch CT, Riera M, Schuettfort G, Silverberg MJ, Smith C, Stecher M, Sterling TR, Ingle SM, Sabin CA, Sterne JAC. Associations of modern initial antiretroviral drug regimens with all-cause mortality in adults with HIV in Europe and North America: a cohort study. Lancet HIV. 2022; 9(6). DOI:10.1016/S2352-3018(22)00046-7. PMID:35659335. IF:16,1 (Q1/1D). Document type: Article.
Yeregui E, Masip J, Vilades C, Domingo P, Pacheco YM, Blanco J, Mallolas J, Alba V, Vargas M, Garcia G, Negredo E, Olona M, Vidal J, Peraire M, Marti A, Reverte L, Gomez F, Leal M, Vidal F, Peraire J, Rull A. Adipokines as New Biomarkers of Immune Recovery: Apelin Receptor, RBP4 and ZAG Are Related to CD4(+) T-Cell Reconstitution in PLHIV on Suppressive Antiretroviral Therapy. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(4):2202. DOI:10.3390/ijms23042202. PMID:35216318. IF:5,6 (Q1/3D). Document type: Article.

Publicacions 2021

Alserawan L, Penacoba P, Echevarria S, Castillo D, Ortiz E, Martinez L, Naranjo EM, Domingo P, Castellvi I, Juarez C, Mariscal A. Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19. Diagnostics. 2021; 11(11):1998. DOI:10.3390/diagnostics11111998. PMID:34829345. IF:3,992.
Amele S, Peters L, Rodger A, Lundgren J, Rockstroh J, Matulionyte R, Leen C, Jablonowska E, Ostergaard L, Bhagani S, Sarcletti M, Clarke A, Falconer K, Wandeler G, Domingo P, Maltez F, Zaccarelli M, Chkhartisvili N, Szlavik J, Stephan C, Fonquernie L, Aho I, Mocroft A, Group ES. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 2021; 86(2). DOI:10.1097/QAI.0000000000002541. PMID:33079903. IF:3,771.
Arroyo JA, Julve J, Vlacho B, Corcoy R, Ponte P, Roman E, Navas E, Llaurado G, Franch J, Domingo P, Mauricio D. Previous Vitamin D Supplementation and Morbidity and Mortality Outcomes in People Hospitalised for COVID19: A Cross-Sectional Study. Frontiers in Public Health. 2021; 9:758347. DOI:10.3389/fpubh.2021.758347. PMID:34631653. IF:6,461.
Berenguer J, Borobia AM, Ryan P, Rodriguez J, Bellon JM, Jarrin I, Carratala J, Pachon J, Carcas AJ, Yllescas M, Arribas JR, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Mancebo J, MARTIN A. Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. THORAX. 2021; 76(9). DOI:10.1136/thoraxjnl-2020-216001. PMID:33632764. IF:9,102.
Brochado O, Martinez I, Berenguer J, Medrano L, Gonzalez J, Jimenez MA, Carrero A, Hontanon V, Navarro J, Guardiola JM, Fernandez A, Resino S, Domingo P, Esteban H. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients. JOURNAL OF BIOMEDICAL SCIENCE. 2021; 28(1):23. DOI:10.1186/s12929-021-00718-6. PMID:33785040. IF:12,771.
Camps A, Perez S, Subirana I, Teira R, Estrada V, Domingo P, Degano IR, Marrugat J. Standardized Comparison of Cardiovascular Risk Factors Prevalence in Spanish Women and Men Living with HIV and in the General Population. Journal of Personalized Medicine. 2021; 11(11):1085. DOI:10.3390/jpm11111085. PMID:34834438. IF:3,508.
Cereijo R, Quesada T, Gavalda A, Tarasco J, Pellitero S, Reyes M, Puig M, Giralt M, Sanchez D, Villarroya F. The chemokine CXCL14 is negatively associated with obesity and concomitant type-2 diabetes in humans. INTERNATIONAL JOURNAL OF OBESITY. 2021; 45(3). DOI:10.1038/s41366-020-00732-y. PMID:33414488. IF:5,551.
Corbacho N, Mur I, Molas ME, Vidal F, Domingo P. The pharmacological management of cardiovascular disease in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(6). DOI:10.1080/14656566.2020.1856075. PMID:33283570. IF:4,103.
Corominas H, Castellvi I, Diaz C, Matas L, de la Rosa D, Mangues MA, Moya P, Pomar V, Benito N, Moga E, Hernandez N, Casademont J, Domingo P. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2. MEDICINE. 2021; 100(19):e25923. DOI:10.1097/MD.0000000000025923. PMID:34106658. IF:1,817.
Corominas H, Castellvi I, Pomar V, Antonijoan R, Mur I, Matas L, Gich I, de Benito N, Laiz A, Castillo D, Villamarin L, Filella D, Mill AM, Quijada MA, Puig M, Casademont J, Domingo P. Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort. CLINICAL IMMUNOLOGY. 2021; 223:108631. DOI:10.1016/j.clim.2020.108631. PMID:33189888. IF:10,190.
Domingo P, Pomar V, Mur I, Castellvi I, Corominas H, de Benito N. Not all COVID-19 pandemic waves are alike. CLINICAL MICROBIOLOGY AND INFECTION. 2021; 27(7). DOI:10.1016/j.cmi.2021.04.005. PMID:33887469. IF:13,310.
Elias MJP, Alejos B, Gutierrez MM, Crespo M, Gil ID, Ribera E, Galindo MJ, Lozano F, Cifre AP, Boix V, Montero M, Sanz J, Lima JD, Palacios R, Moral SDF, Martinez E. Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(4). DOI:10.1093/jac/dkaa547. PMID:33501995. IF:5,758.
Fernández I, de Lazzari E, Inciarte A, Diaz-Brito V, Milinkovic A, Arenas-Pinto A, Etcheverrry F, García F, Leal L; HIV-PEP Group [Domingo P]. Network meta-analysis of post-exposure prophylaxis randomized clinical trials. HIV Medicine. 2021;22(3):218-224. DOI:10.1111/hiv.12964. PMID: 33108035. IF:3,094.
Gonzalez A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masia M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martinez E. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2021; 76(9). DOI:10.1093/jac/dkab158. PMID:34120186. IF:5,758.
Grau B, Camprubi D, Marti H, Fernandez M, Carreras C, Velasco M, Ferrer E, Muelas M, Jullien S, Barilaro G, Ajanovic S, Vera I, Moreno L, Gonzalez E, Cortes N, Roldan M, Artes A, Mur I, Domingo P, Garcia F, Guinovart C, Munoz J. Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial. Trials. 2021; 22(1):808. DOI:10.1186/s13063-021-05758-9. PMID:34781981. IF:2,728.
Gutierrez B, del Toro MD, Borobia AM, Carcas A, Jarrin I, Yllescas M, Ryan P, Pachon J, Carratala J, Berenguer J, Arribas JR, Rodriguez J, López J, Pascual P, Pomar V, Rabella N, Benito N, Domingo P, Bonfill X, Puig M, Mancebo J, Martinez G. Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study. LANCET INFECTIOUS DISEASES. 2021; 21(6). DOI:10.1016/S1473-3099(21)00019-0. PMID:33636145. IF:71,421.
Gutierrez MD, Mur I, Mateo MG, Vidal F, Domingo P. Pharmacological considerations for the treatment of COVID-19 in people living with HIV (PLWH). EXPERT OPINION ON PHARMACOTHERAPY. 2021; 22(9). DOI:10.1080/14656566.2021.1887140. PMID:33634724. IF:4,103.
Kowalska JD, Pelchen A, Ryom L, Losso MH, Trofimova T, Mitsura VM, Khromova I, Paduta D, Stephan C, Domingo P, Bakowska E, Monforte AD, Oestergaard L, Jablonowska E, Kuznetsova A, Moreno S, Vasylyev M, Pradier C, Battegay M, Vandekerckhove L, Castagna A, Raben D, Mocroft A, EuroSIDA GRP. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period. AIDS. 2021; 35(12). DOI:10.1097/QAD.0000000000002954. PMID:34033590. IF:4,632.
Nomah DK, Reyes J, Diaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco RM, Llibre JM, Domingo P, Falco V, Imaz A, Cortes C, Force L, Letang E, Vilaro I, Casabona J, Miro JM, Mur I, Macorigh L. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV. 2021; 8(11). DOI:10.1016/S2352-3018(21)00240-X. PMID:34655549. IF:16,070.
Ortega E, Corcoy R, Gratacos M, Claramunt FXC, Mata M, Puig R, Real J, Vlacho B, Castelblanco E, Domingo P, Khunti K, Franch J, Mauricio D. Risk factors for severe outcomes in people with diabetes hospitalised for COVID-19: a cross-sectional database study. BMJ Open. 2021; 11(7):e051237. DOI:10.1136/bmjopen-2021-051237. PMID:34301668. IF:3,006.
Palacio J, Reyes JM, Imaz A, Bruguera A, Force L, Llaveria AO, Llibre JM, Vilaro I, Borras FH, Falco V, Riera M, Domingo P, de Lazzari E, Miro JM, Casabona J, Gurgui M, Hernandez J. Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review. BMC PUBLIC HEALTH. 2021; 21(1):1596. DOI:10.1186/s12889-021-11613-y. PMID:34454444. IF:4,135.
Reyes M, Gonzalez L, Ibeas K, Cereijo R, Taxeras SD, Pellitero S, Martinez E, Tarasco J, Moreno P, Malagon P, Higueras C, Soria A, Puig M, Villarroya F, Serra D, Herrero L, Sanchez D. White adipose tissue-infiltrated CD11b+myeloid cells are a source of S100A4, a new potential marker of hepatic damage. EUROPEAN JOURNAL OF ENDOCRINOLOGY. 2021; 184(4). DOI:10.1530/EJE-20-1130. PMID:33524007. IF:6,558.
Rivera A, Sanchez A, Luque S, Mur I, Puig L, Crusi X, Gonzalez JC, Sorli L, Gonzalez A, Horcajada JP, Navarro F, Benito N. Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics-Basel. 2021; 10(1):18. DOI:10.3390/antibiotics10010018. PMID:33375415. IF:5,222.
Rojas J, de Lazzari E, Negredo E, Domingo P, Tiraboschi J, Ribera E, Abdulghani N, Puig J, Mateo MG, Podzamczer D, Gutierrez MM, Paredes R, Clotet B, Gatell JM, Blanco JL, Martinez E, DOLAM GRP. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial. Lancet HIV. 2021; 8(8). PMID:34358497. IF:16,070.
Shankar M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, Berry LR, Broman N, Cavalcanti AB, Colman R, De Buyser SL, Derde LPG, Domingo P, Omar SF, Fernandez A, Feuth T, Garcia F, Garcia R, Gonzalez I, Gordon AC, Haynes R, Hermine O, Horby PW, Horick NK, Kumar K, Lambrecht BN, et al. [Pomar V, Benito N]. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2021; 326(6). DOI:10.1001/jama.2021.11330. PMID:34228774. IF:157,335.
Teira R, Diaz H, Aragao F, Marguet S, de la Fuente B, Munoz MJ, Abdulghani N, Ribera E, Domingo P, Deig E, Peraire J, Roca B, Montero M, Galindo MJ, Romero A, Espinosa N, Lozano F, Merino MD, Martinez E, Geijo P, Estrada V, Garcia J, Sepulveda MA, Berenguer J. Real world effectiveness of standard of care triple therapy versus two-drug combinations for treatment of people living with HIV. PLoS One. 2021; 16(4):e0249515. DOI:10.1371/journal.pone.0249515. PMID:33831047. IF:3,752.
Teira R, Diaz H, Aragao F, Munoz J, Galindo P, Merino M, de la Fuente B, Sepulveda MA, Domingo P, Garcia J, Castano M, Ribera E, Geijo P, Romero A, Peraire J, Deig E, Roca B, Martinez E, Estrada V, Montero M, Berenguer J, Espinosa N. eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort. HIV Research & Clinical Practice. 2021; 22(3). DOI:10.1080/25787489.2021.1955197. PMID:34410219. IF:1,676.
Urraza AI, Giralt M, Gonzalez FF, Villarroya F, Perez A, Flores PR, Perez M, Domingo P, Lopez FC. FGF21 serum levels are related to insulin resistance, metabolic changes and obesity in Mexican people living with HIV (PLWH). PLoS One. 2021; 16(5):e0252144. DOI:10.1371/journal.pone.0252144. PMID:34019585. IF:3,752.
Vilchez HH, Escudero R, Fernandez M, Murillo O, Aunon A, Rodriguez D, Jover A, del Toro MD, Rico A, Falgueras L, Praena J, Guio L, Iribarren JA, Lora J, Benito N, Morata L, Ramirez A, Riera M, Mur I, Coll P, Crusi X, Soriano A. Prosthetic Shoulder Joint Infection by Cutibacterium acnes: Does Rifampin Improve Prognosis? A Retrospective, Multicenter, Observational Study. Antibiotics-Basel. 2021; 10(5):475. DOI:10.3390/antibiotics10050475. PMID:33919103. IF:5,222.

GRUPS ASSOCIATS

Grup de Recerca en VIH i SIDA

Principals línies de recerca

Reptes

Projectes sanitaris

Mecanismes patogènics que alteren la distribució de grassa corporal

Trastorns metabòlics associats al tractament antiretroviral

Composició corporal

Nous fàrmacs antiretrovirals

Risc cardiovascular associat al tractament antiretroviral

Condicions de comorbiditat associades a la infecció per VIH-1

Farmacogenètica (toxicocinètica)

Meningitis bacteriana

Coordinació del grup

Membres

Publicacions 2023

Publicacions 2022

Publicacions 2021

Principals línies de recerca

Reptes

Projectes sanitaris

Mecanismes patogènics que alteren la distribució de grassa corporal

Trastorns metabòlics associats al tractament antiretroviral

Composició corporal

Nous fàrmacs antiretrovirals

Risc cardiovascular associat al tractament antiretroviral

Condicions de comorbiditat associades a la infecció per VIH-1

Farmacogenètica (toxicocinètica)

Meningitis bacteriana

Coordinació del grup

Membres

Publicacions 2023

Publicacions 2022

Publicacions 2021

Institut de recerca de l’hospital de la santa creu i sant pau